What Is a Pharmacy Benefit Manager

By Kevin Fernando · Oct 1, 2026 · 8 min read

A pharmacy benefit manager (PBM) is a company that sits between insurers, employers, pharmacies, and pharmaceutical manufacturers to negotiate drug prices, manage prescription coverage, and process claims. PBMs extract revenue through rebates from drug makers, formulary control, and markups on what they charge employers versus what they pay pharmacies.

A pharmacy benefit manager is the company that stands between you, your insurer, your pharmacy, and the drug manufacturer when you fill a prescription. You do not choose it, you may not see its name on your receipt, and yet it controls whether your prescription is covered, what you pay, and what the pharmacy receives. Understanding what PBMs do requires understanding the actual flow of money and information in prescription drug coverage, because PBMs profit by managing that flow in ways that are simultaneously valuable to some parties and costly to others.

This article explains what PBMs are, how they work, and why their role in drug pricing has become controversial. The explanation is grounded in the actual payment relationships and revenue models that define the industry, not in ideology about whether PBMs are good or bad. That judgment depends on which party's interests you are weighing.

What a pharmacy benefit manager actually is

A pharmacy benefit manager is a company that administers prescription drug benefits on behalf of insurers and employers. It negotiates prices with pharmaceutical manufacturers and pharmacies, maintains lists of covered drugs called formularies, processes prescription claims, and manages prior authorization requests. The PBM sits in the middle of four relationships: with the health plan or employer that hires it, with the pharmacies that fill prescriptions, with the drug manufacturers whose products are covered, and with the patients whose claims it processes. It is not a pharmacy, does not manufacture drugs, and does not directly employ doctors or insurers. It is a middleman whose business model depends on managing the information and payment flows between those parties.

How the prescription drug payment flow works

The prescription drug payment system involves multiple simultaneous transactions. When a patient fills a prescription, the pharmacy submits a claim to the PBM, which verifies coverage, applies copayments and deductibles, and determines the reimbursement rate for the pharmacy. The PBM then bills the health plan or employer for its share of the cost. Separately, the PBM negotiates with drug manufacturers for rebates on the drugs it covers. These rebates flow back to the health plan, reducing the overall cost of the drug benefit. The patient sees only the copayment and the pharmacy receipt. The PBM's role is to manage the claim processing, price negotiation, and rebate collection that happens behind that transaction.

The three-party relationship

Each party in the PBM system has different priorities. The health plan or employer wants to minimize the total cost of prescription drug coverage for its members or employees. The pharmacy wants to maximize its reimbursement per prescription filled and maintain steady patient volume. The drug manufacturer wants to maximize the number of prescriptions written for its product and the price paid per prescription. The PBM negotiates with all three, but its loyalty is contractually to the health plan or employer that hired it. That alignment matters because it shapes what the PBM optimizes for and which of its revenue streams create conflicts of interest.

Where PBMs extract value

PBMs generate revenue through three primary mechanisms. First, they negotiate rebates from drug manufacturers and pass most of them back to the health plan, but may retain a portion. Second, they control which drugs appear on the formulary, which drugs require prior authorization, and which tier a drug is placed on, giving them leverage to negotiate better prices. Third, they use spread pricing: they pay pharmacies one amount and bill the health plan a higher amount, retaining the difference as revenue. For example, a PBM might pay a pharmacy $80 for a prescription but bill the plan sponsor $100, keeping the $20 difference. From 2017 to 2022, PBMs received $8.7 billion in revenue from markups and spread pricing, with markups accounting for 12% of their parent companies' income, up from less than 8% two years earlier.

A worked example of how a PBM processes a claim

Suppose a patient has a health plan administered by a PBM and fills a prescription for a generic drug. The pharmacy submits the claim electronically to the PBM. The PBM checks whether the drug is on the formulary and what tier it is on. If it is a preferred generic, the patient's copayment might be $10. The PBM then determines what it will pay the pharmacy. The pharmacy and patient each receive reimbursement or pay their portion. The health plan pays the PBM an amount that covers the pharmacy reimbursement and the patient's copayment. If the PBM negotiated a rebate from the drug manufacturer for high volume on that drug, that rebate flows separately to the health plan, reducing its net cost. The patient never sees the rebate, the pharmacy never sees the rebate, and the PBM's role in negotiating it is invisible in the claim itself. This is the basic flow for every prescription: claim submission, formulary check, reimbursement determination, and claim settlement.

How PBMs originated and evolved

Pharmacy benefit managers emerged in the United States in the 1960s when large insurance companies began offering prescription drug benefits as part of health insurance. The original value proposition was straightforward: PBMs could centralize claims processing, negotiate with pharmacies to create a network, and offer mail-order pharmacy services. When PBMs first entered the market, they could provide claims processing, mail service, and a network of pharmacies, saving employers 15 to 20 percent. That was a genuine efficiency gain. Employers did not have the infrastructure to manage pharmacy networks themselves, and PBMs provided it at scale. Over decades, PBMs consolidated. Today, three companies control 80% of the market: Express Scripts processed 2.22 billion prescription claims in 2025 and held 31% market share, CVS Caremark processed 1.9 billion claims and held 26%, and Optum Rx held 23%. As they grew, their business model shifted from pure claims processing to revenue generation through rebate negotiation, formulary control, and spread pricing. The original efficiency function remains, but it is now intertwined with profit extraction that did not exist in the 1960s.

The structural tensions in PBM economics

PBM business models create several structural conflicts that have drawn regulatory scrutiny. The fundamental tension is that PBMs are paid by health plans to reduce drug costs, but they also profit by charging those same health plans more for drugs than they pay pharmacies and by retaining rebates. These incentives are not always aligned. A PBM could theoretically maximize its own revenue by negotiating lower rebates from manufacturers in exchange for favorable formulary placement, then charging the health plan higher prices for those drugs. The health plan bears the cost while the PBM captures the spread. Similarly, PBMs that own affiliated specialty pharmacies have an incentive to route prescriptions to those pharmacies and mark them up aggressively. The Big 3 PBMs and their affiliated specialty pharmacies generated more than $7.3 billion in revenue from dispensing drugs in excess of their estimated acquisition costs from 2017 to 2022. Of specialty generic drugs dispensed by PBM-affiliated pharmacies, 63% were marked up by more than 100%, and 22% had markups over 1,000%. These markups exceed what independent pharmacies charge, creating a financial incentive for PBMs to direct volume to their own pharmacies rather than to independent ones.

Conflicts between PBM incentives and patient access

PBMs use prior authorization and formulary restrictions to manage costs and negotiate rebates, but these tools also restrict patient access to medications. A PBM might require prior authorization for a drug not because it is unsafe or ineffective, but because the manufacturer has not negotiated a favorable rebate. A patient whose doctor prescribes a drug off the formulary must wait for approval, or the patient pays out of pocket. The PBM profits from the rebate negotiation; the patient bears the cost of the delay or the expense. Similarly, PBMs tier formularies to incentivize use of cheaper drugs, which can be medically appropriate, but they also tier drugs based on rebate amounts rather than clinical evidence. A more expensive branded drug with a larger rebate might be placed on a lower tier than a cheaper generic with no rebate, even if the generic is clinically preferred. The health plan sees a rebate and thinks it is saving money; the patient sees a higher copayment and cannot afford the drug. These are not failures of the system; they are features of a system where the PBM's revenue depends on managing the tension between cost and access.

Consolidation and vertical integration concerns

The concentration of the PBM market raises structural concerns about conflicts of interest. Three companies control 80% of the market, and two of them (CVS Caremark and Optum Rx) are owned by larger health companies. CVS Caremark is owned by CVS Health, which also owns a major pharmacy chain and health insurance plans. Optum Rx is owned by UnitedHealth Group, which owns a major health insurance company. When a PBM is owned by an insurer or pharmacy chain, it has incentives to favor its parent company's interests over its clients' interests. An insurer-owned PBM might negotiate lower rebates if it benefits the insurer's overall business, even if it costs the PBM's employer clients more. A pharmacy-owned PBM might route prescriptions to its affiliated pharmacies at higher markups. These conflicts are not necessarily illegal, but they are structural: they arise from the business model, not from individual misconduct. Regulators have raised concerns about whether vertical integration in the PBM industry reduces competition and raises costs for employers and patients.

What PBMs actually control in the drug market

It is common to overstate PBM power in drug pricing. PBMs do not set drug prices; manufacturers do. PBMs do not approve drugs; the FDA does. PBMs do not write prescriptions; doctors do. What PBMs actually control is formulary placement, prior authorization requirements, and reimbursement rates to pharmacies. They negotiate with manufacturers over rebates in exchange for formulary placement. They negotiate with pharmacies over reimbursement rates in exchange for network inclusion. They process claims and manage the flow of information between all parties. This is significant power over which drugs get used and how much they cost, but it is constrained power. A manufacturer can refuse to negotiate and charge cash prices; patients can appeal prior authorization decisions; doctors can prescribe off-formulary drugs. PBMs are powerful intermediaries, but they operate within constraints set by manufacturers, regulators, patients, and doctors. They do not unilaterally control drug pricing or access.

How PBMs connect to adjacent concepts

Understanding PBMs requires understanding the tools they use and the regulatory environment they operate in. A formulary is the list of drugs a PBM covers and the tier each drug is on; understanding how formularies are constructed is essential to understanding how PBMs influence drug use. Prior authorization is the requirement that a doctor get approval from the PBM before the patient can fill a prescription; understanding when and why PBMs require it is essential to understanding how they manage access. Spread pricing is the difference between what a PBM pays a pharmacy and what it charges a health plan; understanding spread pricing is essential to understanding PBM revenue. The regulatory landscape around PBMs is evolving. State legislatures have passed laws limiting spread pricing and requiring PBM transparency. The Federal Trade Commission has investigated PBM practices and issued reports on markups and rebate arrangements. Congress has held hearings on PBM consolidation. A reader who wants to understand drug pricing in the United States needs to understand not just what PBMs are, but how formularies work, how prior authorization works, and what the current regulatory debate is about.

Do this automatically

A health plan administrator manually processing thousands of daily pharmacy claims, verifying coverage eligibility, cross-referencing formularies, calculating patient cost-sharing, and reconciling rebates from manufacturers, would require substantial labor hours multiplied across every prescription filled each year. Software systems can automate these simultaneous transactions across the entire claims pipeline, from initial pharmacy submission through final adjudication and reporting. Healthcare research runs this kind of analysis end to end and cites every figure back to its original source, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.

Start your first report and run it on something you already know well.

This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.